SNY Sanofi
Company Analysis
Latest News
Retension Prices $45 Million IPO; Blueprint Plans 229 Layoffs
Retension Pharmaceuticals, a clinical-stage biopharmaceutical company, priced its upsized initial public offering on October 9, 2026. The IPO is expected to...
Sanofi and Regeneron Add Four Antibodies in $8 Billion Deal
Sanofi and Regeneron have expanded their two-decade antibody collaboration, which produced blockbuster drug Dupixent. Sanofi will pay Regeneron $1 billion...
Sanofi Faces Florida Suit Alleging Insulin Price-Fixing
Florida Attorney General James Uthmeier filed an antitrust lawsuit on September 25, 2026, against Sanofi, Eli Lilly, Novo Nordisk and other major insulin...
🟢 Sanofi is trading 4.3% up in after-hours trading; catalyst remains unclear
Sanofi is trading 4.28% up at $44.30 in after-hours trading, with no verified company-specific announcement identified for September 18, 2026. - Sanofi’s...
Sanofi Rations Pompe Disease Drugs, Citing FDA Manufacturing Warning
Sanofi is experiencing a shortage of two medications for Pompe disease. Pompe disease is a rare genetic disorder. The supply constraint is forcing some...
Sanofi Crushed Its Quarter — So Why Are Investors Running for the Exit?
Shares of Sanofi sank 6.8% to $41.82 today even after the French drugmaker posted a Q2 that cleared every hurdle Wall Street set. The disconnect tells a...
🔴 Sanofi is trading 7.1% down today on strategy shift and pipeline cuts
Sanofi is trading 7.1% down at $41.82 following the release of its Q2 2026 results and a significant update to its corporate strategy. • While the company...
🔴 Sanofi Shares Fall 4.3% as Investors Focus on New CEO's Strategy and Pipeline Cuts Despite Q2 Revenue Beat and Raised Guidance
Sanofi is trading at $42.92 (-4.29%) in pre-market, with shares declining following its Q2 2026 earnings report today. • The pharmaceutical giant reported Q2...
Sanofi Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Sanofi is expected to report Q2 2026 revenue of $12.14 billion and EPS of $1.09, while the stock’s current price of $54.85 sits below the average analyst...
Sanofi Scraps Eczema Drug Amlitelimab, Citing Lack of Competitive Edge
Sanofi discontinued clinical development of amlitelimab for moderate-to-severe atopic dermatitis. The company will not seek global regulatory approval for the...
Sanofi Reshuffles Executive Leadership, Consolidating Finance and China Oversight
Sanofi will overhaul its Executive Committee effective September 1, 2026. The restructuring aims to streamline leadership for the company’s next strategic...
Sanofi Wins FDA Approval for First Wearable Cancer Injector, Cutting Treatment Time
The U.S. Food and Drug Administration (FDA) approved Sanofi's Sarclisa Escena (isatuximab-irfc) for multiple myeloma treatment. This subcutaneous formulation...
Sanofi seeks FDA approval, Nexviazyme hits goals in rare infant disease
Sanofi announced on June 30, 2026, that Nexviazyme met all primary and secondary goals in its Phase 3 Baby-COMET study. The trial evaluated the drug in...
Sanofi faces EU antitrust probe, allegedly disparaging rival Fluad vaccine
The European Commission launched a formal antitrust investigation into Sanofi for alleged anticompetitive practices. Regulators are probing whether the French...
Sanofi Secures Japan Approval for Wayrilz to Treat Rare Blood Disorder
Japan's Ministry of Health, Labour and Welfare approved Sanofi's Wayrilz (rilzabrutinib) for chronic immune thrombocytopenia (ITP). This rare autoimmune...
Sanofi secures EU approval for Cenrifki, first treatment for non-relapsing SPMS
The European Commission approved Sanofi’s drug Cenrifki (tolebrutinib) for adults with secondary progressive multiple sclerosis (SPMS) without recent relapses....
Sanofi Appoints Roche Veteran Paulo Fontoura as New Global Head of R&D
Sanofi has named Paulo Fontoura as its new Executive Vice President and Global Head of Pharma Research & Development, effective September 1, 2026. The...
Sanofi Reports Long-Term Riliprubart Gains in CIDP, Countering Phase 3 Setback
Sanofi reported new Phase 2 trial findings for riliprubart at the 2026 Peripheral Nerve Society Annual Meeting. Long-term treatment over 76 weeks led to...
Sanofi’s Tzield wins FDA approval for youth, slowing diabetes progression
The FDA granted accelerated approval for Sanofi’s Tzield (teplizumab-mzwv) for patients aged 8 to 17. This indication targets children and adolescents recently...
Sanofi Q1 2026 Earnings Preview: What Analysts Expect on April 23, 2026
Sanofi is expected to report Q1 2026 revenue of $11.99 billion and EPS of $1.04, with the stock currently trading near $48.06 compared to an average analyst...